Professor Brendan Jenkins
A Novel Translational Pipeline for the Introduction of New Immune-Based Therapies Targeting Localised and Metastatic Pancreatic Ductal Adenocarcinoma
Grant
A Novel Translational Pipeline for the Introduction of New Immune-Based Therapies Targeting Localised and Metastatic Pancreatic Ductal Adenocarcinoma
Award
Innovation Grant 2017
Institution
Hudson Institute of Medical Research
Principal Investigator
Professor Brendan Jenkins, Deputy Director, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research
Time required to complete project
1 year
Project Summary
This project aims to show the preclinical efficacy of a novel series of immune-based therapies across a range of human pancreatic tumours which have been genetically screened to predict treatment responsiveness. This project also addresses the need to identify new genes that can be the target of novel therapeutic approaches.
Research Reports
Click to download progress reporting on the outcomes of this research.